Cardiff Oncology Inc. (NASDAQ: CRDF) will present updated Phase 2 trial data for its cancer drug onvansertib at the 2026 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE